Innovation Momentum Driven by a Hundred-Billion-Dollar Market: Three Key Investigational Drugs from Jiangsu Hengrui Accelerate Development

✍️ Written by DengyueMed

Against the backdrop of the global pharmaceutical industry’s ongoing transition toward innovation-driven growth, Chinese drugmakers are accelerating the development of novel therapeutics and expanding their international footprint. Recently, several investigational innovative drug candidates from Jiangsu Hengrui Pharmaceuticals have attracted increasing industry attention, including HRS-7525 tablets, SHR-A2102 for injection, and sudide insulin–noliglutide injection.

These three products respectively target precision oncology therapies, antibody–drug conjugates (ADCs), and metabolic diseases such as diabetes, all of which are therapeutic areas experiencing rapid market expansion. Industry analysts suggest that in an increasingly competitive global drug market, diversified innovation pipelines across multiple therapeutic modalities have become a key strategy for large pharmaceutical companies to enhance long-term competitiveness.

Expansion of the Targeted Therapy Market: Development Opportunities for HRS-7525

Precision targeted therapy remains a major growth engine for the global oncology drug market. Data indicate that the global oncology therapeutics market exceeded USD 200 billion in 2024 and is projected to surpass USD 350 billion by 2030. Small-molecule targeted agents continue to account for a significant share, particularly in high-incidence malignancies such as lung cancer, breast cancer, and gastrointestinal tumors, where demand remains strong.

HRS-7525 tablets represent one of Hengrui’s key strategic initiatives in next-generation targeted therapies, aligning with industry trends toward improved target selectivity, reduced toxicity, and optimized resistance management.

Potential advantages may include:

● Improved target specificity with reduced off-target toxicity

● Flexibility for incorporation into combination treatment regimens

● Oral administration that may enhance long-term treatment adherence

From a commercialization perspective, oral targeted therapies benefit from relatively mature manufacturing processes and higher patient convenience, supporting their sustained growth potential in the global market.

ADC Field Enters a Rapid Growth Phase: SHR-A2102 Strengthens Competitive Positioning

In recent years, antibody–drug conjugates have been widely regarded as one of the most promising segments in oncology innovation. Industry reports project that the global ADC market will expand from approximately USD 10 billion in 2023 to over USD 60 billion by 2030, representing a compound annual growth rate exceeding 25%.

SHR-A2102 for injection, a key candidate within Hengrui’s ADC technology platform, reflects the company’s continued investment in antibody engineering, linker optimization, and cytotoxic payload development.

As ADC indications expand from hematologic malignancies to solid tumors, competition in this field is intensifying.

Key trends attracting industry attention include:

● Combination strategies with immunotherapy to enhance efficacy

● Development of novel payloads to improve safety profiles

● Target diversification enabling broader therapeutic indications

Moreover, the potential of ADCs in combination regimens—such as with immune checkpoint inhibitors or targeted agents—is widely expected to further improve treatment outcomes in oncology.

Rising Demand in Diabetes Care: Significant Market Potential for Next-Generation Glucose-Lowering Therapies

Within the chronic disease landscape, diabetes has become a major global public health challenge. International data suggest that the number of people living with diabetes worldwide has exceeded 500 million, with continued growth anticipated before 2030. Driven by expanding patient populations and therapeutic upgrading, the global diabetes drug market is projected to surpass USD 120 billion by 2030.

The development of sudide insulin–noliglutide injection aligns with the ongoing shift in treatment paradigms from simple glycemic control toward comprehensive metabolic management. In recent years, therapies associated with the GLP-1 pathway have demonstrated strong commercial performance worldwide, with some products achieving annual sales exceeding USD 10 billion.

Experts note that next-generation antidiabetic therapies may offer potential advantages in weight management, cardiovascular risk reduction, and long-term treatment adherence, making them a key focus area for pharmaceutical innovation.

Multi-Platform Innovation Strategy Enhances Global Competitiveness

From the small-molecule targeted positioning of HRS-7525, to the advancement of the ADC platform represented by SHR-A2102, and the exploration of metabolic disease therapies with sudide insulin–noliglutide injection, Hengrui is building an innovation ecosystem covering the dual core markets of oncology and chronic diseases.

Industry analysis suggests that multi-platform collaborative R&D can improve technological leverage while also generating scale advantages in global clinical development and market access. In recent years, Chinese innovative pharmaceutical companies have strengthened international collaborations and overseas clinical trial deployment, steadily enhancing global recognition.

Data show that outbound licensing transactions involving Chinese innovative drugs have continued to rise, exceeding USD 40 billion in 2023, reflecting growing international confidence in China’s R&D capabilities.

Industry Outlook: Value-Driven Innovation Becomes the New Competitive Paradigm

Overall, the therapeutic areas targeted by Hengrui’s three investigational drugs offer substantial growth potential. As the global pharmaceutical industry enters a phase increasingly defined by clinical value and differentiated innovation, the ability to consistently deliver products with clear therapeutic advantages will be critical for sustained long-term growth.

Industry consensus suggests that over the next five to ten years, precision targeted therapies, ADC technologies, and innovative metabolic disease treatments will remain key drivers of global pharmaceutical market expansion.

As more clinical data become available, the market performance and therapeutic value of HRS-7525 tablets, SHR-A2102 for injection, and sudide insulin–noliglutide injection will continue to be closely monitored by stakeholders across the industry.